Ground Zero Pharmaceuticals (GZP) is expanding its capabilities to provide services for biosimilar development, drug or biologic/diagnostic device, and personalized medicine programs for FDA and EMA review. GZP’s CMC offers pharmacology/ toxicology, clinical and regulatory experts to help companies navigate the complexities of biosimilar programs, such as associated planning and execution of nonclinical and clinical programs.   GZP has been working with clients to develop and test prognostic/dia...